Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma

Leukemia and Lymphoma

Volumn 44, Issue 1, 2003, Pages 29-37

  Kouroukis, C Tom ^a,b,c   O'Brien, Bernie J ^c,d   Benger, Ann ^a,b,c   Marcellus, Deborah ^a,b,c   Foley, Ronan ^b,c   Garner, Jane ^b   Ingram, Carol ^b   Haines, Patricia ^a   Henderson O'Connor, Nancy ^b   Meyer, Ralph ^a,b,c  

^a CANCER CARE ONTARIO   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

Cost effectiveness; High dose chemotherapy; Multiple myeloma; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANADA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; GRAFT REJECTION; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MALE; MULTIPLE MYELOMA; PATIENT REFERRAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FINANCING, ORGANIZED; HEALTH EXPENDITURES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE MYELOMA; PREDNISONE; SURVIVAL ANALYSIS;

EID: 0037234955     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000040260     Document Type: Article

References (32)

1. Osgood, E. (1960) "The survival time of patients with plasmacytic myeloma", Cancer Chemotherapy Reports 9, 1-10.
2. Alexanian, R., Bonnet, J., Gehan, E., Haut, A., Hewlett, J., Lane, M., Monto, R. and Wilson, H. (1972) "Combination chemotherapy for multiple myeloma", Cancer 30, 382-389.
3. Gregory, W., Richards, M. and Malpas, J. (1992) "Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials", Journal of Clinical Oncology 10, 334-342.
4. Myeloma Trialists' Collaborative Group. (1998) "Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials", Journal of Clinical Oncology 16, 3822-3842.
5. For the Myeloma Trialists' Collaborative Group (MTCG) Wheatley, K. (1998) "The role of interferon (IFN) as therapy for multiple myeloma: an overview of 24 randomized trials with over 4000 patients", Proceedings of the American Society of Clinical Oncology 17, 8a.
6. Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1996) "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", New England Journal of Medicine 335, 91-97.
7. Durie, B. and Salmon, S. (1975) "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival", Cancer 36, 842-854.
8. Uyl-de Groot, C., Ossenkoppele, G., van Riet, A. and Rutten, F. (1994) "The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma", European Journal of Cancer 30A, 457-459.
9. Duncan, N., Hewetson, M., Powles, R., Raje, N. and Mehta, J. (1996) "An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma", Bone Marrow Transplantation 18, 1175-1178.
10. Jagannath, S., Vesole, D.H., Zhang, M., Desikan, K.R., Copeland, N., Jagannath, M., Bracy, D., Jones, R., Crowley, J., Tricot, G. and Barlogie, B. (1997) "Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma", Bone Marrow Transplantation 20, 445-450.
11. Henon, P., Donatini, B., Eisenmann, J.C., Becker, M. and Beck-Wirth, G. (1995) "Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma", Bone Marrow Transplantation 16, 19-25.
12. Trippoli, S., Messori, A., Becagli, P., Alternini, R. and Tendi, E. (1998) "Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation", Oncology Reports 5, 1475-1482.
13. Sampson, F., Beard, S., Scott, F. and Vandenberghe, E. (2001) "Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma", British Journal of Haematology 113, 1015-1019.
14. Browman, G., Bergsagel, D., Sicheri, D., O'Reilly, S., Wilson, K., Rubin, S., Belch, A., Shustik, C., Barr, R., Walker, L, James, K., Zee, B. and Johnston, D. (1995) "Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group", Journal of Clinical Oncology 13, 2354-2360.
15. Barlogie, B., Smith, L. and Alexanian, R. (1984) "Effective treatment of advanced multiple myeloma refractory to alkylating agents", New England Journal of Medicine 310, 1353-1356.
16. Norman, G. and Streiner, D. (1998) Biostatistics the Bare Essentials (B.C. Decker, Hamilton, Ontario).
17. Statistics Canada CANSIM. (2000) Consumer price index, 1996 classification, annual average indexes, Canada and provinces, Ottawa.
18. Ministry of Health and Long-Term Care. (2001) Ontario Drug Benefit Formulary, 37.
19. Ontario Ministry of Health and Long-Term Care. (2000) Schedule of Benefits. Physician Services Under the Health Insurance Act.
20. Ortega, A., Dranitsaris, G. and Puodziunas, A. (1998) "A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy", International Journal of Technology Assessment in Health Care 14, 788-798.
21. The Canadian Cost of Transfusion Study Group Tretiak, R., Laupacis, A., Rivière, M., McKerracher, K. and Souêtre, E. (1996) "Cost of allogeneic and autologous blood transfusion in Canada", Canadian Medical Association Journal 154, 1501-1508.
22. Kaplan, E. and Meier, P. (1958) "Nonparametric estimation from incomplete observations", Journal of the American Statistical Association 53, 457-485.
23. Fleiss, J. (1973) Statistical Methods for Rates and Proportions (John Wiley, New York).
24. Fisher, R. (1970) Statistical Methods for Research Workers (Hafner Press, New York).
25. Mantel, N. (1966) "Evaluation of survival data and two new rank order statistics arising in its consideration", Cancer Chemotherapy Reports 50, 163-170.
26. Viscusi, W. (1995) "Discounting health effects for medical decisions", In: Sloan, F., ed, Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Medical Technologies (Cambridge University Press, New York), pp. 123-145.
27. Donatini, B., Henon, P. and Becker, M. (1994) "Peripheral blood stem cell transplantation in multiple myeloma. Clinical benefits and cost analysis", British Journal of Medical Economics 7, 55-62.
28. Kukull, W., Koepsell, T. and Conrad, D. (1986) "Rapid estimation of hospitalization charges from a brief medical record review: evaluation of multivariate prediction model", Medical Care 24, 961-966.
29. Bulpitt, C. and Fletcher, A. (1990) "The measurement of quality of life in hypertensive patients: a practical approach", British Journal of Clinical Pharmacology 30, 353-364.
30. How do the outcomes of patients treated within randomised control trials compare with those of similar patients treated outside these trials? (2000) http://hiru.mcmaster.ca/edm/trout/
31. Smith, T., Hillner, B. and Desch, C. (1993) "Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis", Journal of the National Cancer Institute 85, 1460-1474.
32. Laupacis, A., Feeny, D., Detsky, A. and Tugwell, P. (1992) "How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations", Canadian Medical Association Journal 146, 473-481.